Vaxcyte (PCVX) Operating Expenses (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Operating Expenses data on file, last reported at $345.8 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $345.8 million, up 91.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 71.22% YoY), and the FY2025 annual result was $923.7 million, up 62.18% from the prior year.
• Operating Expenses climbed to $345.8 million in Q1 2026 per PCVX's latest filing, from $274.3 million in the prior quarter.
• Over five years, Operating Expenses peaked at $345.8 million in Q1 2026 and troughed at $39.2 million in Q1 2022.
• A 5-year average of $149.4 million and a median of $139.9 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2024: Operating Expenses jumped 190.07% in 2022, then decreased 17.55% in 2024.
• A 5-year view of Operating Expenses shows it stood at $86.6 million in 2022, then jumped by 127.18% to $196.7 million in 2023, then declined by 17.55% to $162.2 million in 2024, then surged by 69.13% to $274.3 million in 2025, then climbed by 26.09% to $345.8 million in 2026.
• Business Quant data shows PCVX's Operating Expenses at $345.8 million in Q1 2026, $274.3 million in Q4 2025, and $242.4 million in Q3 2025.